• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SR. VICE PRESIDENT & CSO Desjarlais John R was granted 29,851 shares, increasing direct ownership by 14% to 246,271 units (SEC Form 4)

    3/5/25 5:05:40 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XNCR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Desjarlais John R

    (Last) (First) (Middle)
    C/O XENCOR, INC.
    465 N HALSTEAD STREET, SUITE 200

    (Street)
    PASADENA CA 91107

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Xencor Inc [ XNCR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SR. VICE PRESIDENT & CSO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/04/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/04/2025 A 29,851(1) A $0 246,271 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $14.15 03/04/2025 A 89,552 (2) 03/04/2035 Common Stock 89,552 $0 89,552 D
    Explanation of Responses:
    1. Represents restricted stock units that vest as follows: 1/3 of the shares vest on the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
    2. 25% of the shares subject to the option shall vest on the one year anniversary of March 4, 2025 (the "Vesting Commencement Date") and 1/48th of the shares shall vest monthly thereafter, such that the option shall be fully vested on the four year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
    /s/ Celia E. Eckert, Attorney-in-Fact 03/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $XNCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XNCR

    DatePrice TargetRatingAnalyst
    4/21/2025Outperform
    William Blair
    12/12/2024$37.00Overweight
    Wells Fargo
    12/2/2024$20.00 → $30.00Neutral → Overweight
    Piper Sandler
    4/16/2024$56.00 → $38.00Buy
    BTIG Research
    2/28/2024$37.00 → $24.00Overweight → Neutral
    Piper Sandler
    5/19/2023$42.00Buy
    BofA Securities
    12/6/2022Outperform
    Cowen
    10/13/2022$58.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $XNCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xencor Reports First Quarter 2025 Financial Results

      -- Recent interim Phase 1 study results for XmAb942 (Xtend™ anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Chief development officer and former independent director, Nancy Valente, M.D., to transition to senior advisory role -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. "Recently presented interim Phase 1 results suppo

      5/7/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

      -- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class -- -- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC -- -- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 -- -- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced

      4/29/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Todd Simpson to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

      3/13/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Development Officer Valente Nancy sold $50,914 worth of shares (4,616 units at $11.03), decreasing direct ownership by 9% to 49,169 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      5/6/25 4:40:24 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SR. VICE PRESIDENT & CFO Cornelissen Bart Jan sold $30,233 worth of shares (3,750 units at $8.06), decreasing direct ownership by 6% to 61,348 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      4/14/25 4:13:39 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Simpson Todd E

      4 - Xencor Inc (0001326732) (Issuer)

      3/13/25 7:03:03 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/14/24 6:16:13 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/14/24 1:22:36 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/12/24 4:01:23 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Xencor Appoints Todd Simpson to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

      3/13/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Bart Cornelissen as Chief Financial Officer

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. "Bart's exceptional track record in financial planning and analysis

      4/9/24 8:01:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors. Dr. Klencke has more than 20 years of biopharmaceutical product development experience, and she most recently served as chief medical officer and chief development officer at Sierra Oncology through mid-2023. While at Sierra Oncology, she built a highly effective clinical development organization and led its strategy and execution, culminating in the approval of Ojjaara™ for myelofibrosis following the company's acquisition by GSK. "D

      9/19/23 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Xencor

      William Blair initiated coverage of Xencor with a rating of Outperform

      4/21/25 8:40:03 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Xencor with a new price target

      Wells Fargo initiated coverage of Xencor with a rating of Overweight and set a new price target of $37.00

      12/12/24 8:18:37 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Xencor from Neutral to Overweight and set a new price target of $30.00 from $20.00 previously

      12/2/24 10:12:11 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Financials

    Live finance-specific insights

    See more

    $XNCR
    SEC Filings

    See more
    • Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

      -- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class -- -- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC -- -- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 -- -- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced

      4/29/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

      – Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3) to be evaluated in autoimmune diseases, with respective Phase 1b/2a and Phase 1 studies to initiate in 2025 – – Ongoing Phase 1 dose escalation of XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma shows initial encouraging clinical activity including RECIST responses – – Management hosting webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT today – Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing

      9/9/24 7:31:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will host a webcast and conference call at 8:00 a.m. ET (5:00 a.m. PT) on Monday, September 9, 2024 to introduce new XmAb® programs in development for the treatment of patients with autoimmune diseases and to provide updates on continued progress in dose escalation with first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) in patients with advanced solid tumors. The live webcast may be accessed through "E

      9/6/24 8:01:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Xencor Inc.

      10-Q - Xencor Inc (0001326732) (Filer)

      5/7/25 4:09:38 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

      8-K - Xencor Inc (0001326732) (Filer)

      5/7/25 4:03:09 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Xencor Inc.

      DEFA14A - Xencor Inc (0001326732) (Filer)

      4/23/25 4:06:50 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gorman Kevin Charles bought $1,013 worth of shares (53 units at $19.12), increasing direct ownership by 1% to 5,060 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      2/15/24 4:02:46 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care